A Study to Evaluate the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Participants With Resected Stage II-III KRAS G12C-Positive Non-Small Cell Lung Cancer (NSCLC) (KRASCENDO 3)
A Phase III, Randomized, Open-label Study Evaluating the Efficacy and Safety of Divarasib Compared With Investigator's Choice of Immunotherapy or Observation in Patients With Resected Stage II-III KRAS G12C-Positive Non-small Cell Lung Cancer
The main purpose of this study is to evaluate the efficacy of divarasib compared with investigator's choice of immunotherapy (pembrolizumab or nivolumab) or observation in participants with resected Kirsten rat sarcoma viral oncogene homolog glycine 12 to cysteine (KRAS G12C)-positive Stage II-IIIB NSCLC, regardless of tumor programmed death-ligand 1 (PD-L1) status, who have not achieved pathologic complete response (pCR) following neoadjuvant chemoimmunotherapy.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Study Contact Backup
- Name: Reference Study ID Number: BO45885 https://forpatients.roche.com/ No attachments to email below.
- Phone Number: 888-662-6728 (U.S. only)
- Email: global-roche-genentech-trials@gene.com
Study Locations
-
-
-
Capital Federal, Argentina, C1122AAL
- Recruiting
- Instituto Argentino de Diagnóstico y Tratamiento- IADT
-
Ciudad Autonoma Buenos Aires, Argentina, C1426AGE
- Recruiting
- Centro Oncologico Korben
-
Ciudad Autonoma Buenos Aires, Argentina, C1280AEB
- Recruiting
- Hospital Britanico
-
Ciudad Autonoma Buenos Aires, Argentina, C1430EGF
- Recruiting
- Clinica Adventista Belgrano
-
Mar del Plata, Argentina, B7602CBM
- Recruiting
- Hospital Privado De Comunidad
-
-
Santa Fe Province
-
Rosario, Santa Fe Province, Argentina, S2000ORE
- Recruiting
- Sanatorio de la Mujer
-
-
-
-
-
Hasselt, Belgium, 3500
- Recruiting
- Jessa Zkh (Campus Virga Jesse)
-
Mons, Belgium, 7000
- Recruiting
- CHU HELORA - Hôpital de Mons - Site Kennedy
-
-
-
-
-
São Paulo, Brazil, 01321-00
- Recruiting
- Beneficencia Portuguesa de Sao Paulo
-
-
Minas Gerais
-
Belo Horizonte, Minas Gerais, Brazil, 30130-090
- Recruiting
- Cenantron - Centro Avancado de Tratamento Oncologico
-
-
Rio Grande do Sul
-
Porto Alegre, Rio Grande do Sul, Brazil, 90610-000
- Recruiting
- Hospital Sao Lucas - PUCRS
-
Porto Alegre, Rio Grande do Sul, Brazil, 90035-001
- Recruiting
- Hospital Moinhos de Vento
-
-
Santa Catarina
-
Itajaí, Santa Catarina, Brazil, 88301-220
- Recruiting
- Clinica de Neoplasias Litoral
-
-
-
-
Quebec
-
Montreal, Quebec, Canada, H4A 3J1
- Recruiting
- McGill University Health Center
-
Montreal, Quebec, Canada, H3T 1E2
- Recruiting
- Jewish General Hospital
-
-
-
-
-
Beijing, China, 100021
- Recruiting
- Beijing Cancer Hospital
-
Changchun, China, 130021
- Recruiting
- The First Hospital of Jilin University
-
Foshan, China
- Recruiting
- The First People's Hospital of Foshan
-
Guangzhou, China, 510030
- Recruiting
- Guangdong General Hospital
-
HangzhouZhejiang, China, 310009
- Recruiting
- The Second Affiliated Hospital of Zhejiang University College
-
Nanchang, China
- Recruiting
- The First Affiliated Hospital of Nanchang University
-
Nanchang, China, 330038
- Recruiting
- The Second Affiliated Hospital of Nanchang University
-
Nanjing, China, 210029
- Recruiting
- Nanjing First Hospital
-
Suzhou, China, 215006
- Recruiting
- The First Affiliated Hospital of Soochow University
-
Taizhou, China, 318050
- Recruiting
- Taizhou Hospital Of Zhejiang Province
-
Tianjin, China, 300060
- Recruiting
- Tianjin Cancer Hospital
-
-
Anhui
-
Hefei, Anhui, China, 230001
- Recruiting
- Anhui Provincial Hospital(The First Affiliated Hospital of USTC)
-
-
Guangdong
-
Shenzhen, Guangdong, China, 518020
- Recruiting
- Shenzhen People's Hospital
-
-
Shandong
-
Jinan, Shandong, China, 250117
- Recruiting
- Cancer Hospital of Shandong First Medical University
-
Jinan, Shandong, China, 250014
- Recruiting
- Shandong Provincial Hospital
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Recruiting
- Sichuan Cancer Hospital
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310016
- Not yet recruiting
- Sir Run Run Shaw Hospital Zhejiang University School of Medicine - Qingchun Campus
-
-
-
-
-
Barranquilla, Colombia, 080020
- Recruiting
- Clinica Bonnadona Prevenir
-
Bogota, D.C., Colombia, 110131
- Recruiting
- Fundación CTIC - Centro de Tratamiento e Investigación sobre Cáncer Luis Carlos Sarmiento Angulo
-
Florindablanca, Colombia
- Recruiting
- FOSCAL
-
Medellín, Colombia, 50010
- Recruiting
- Clinica ASTORGA
-
-
-
-
-
Avignon, France, 84902
- Recruiting
- CH d Avignon
-
Quimper, France, 29107
- Recruiting
- CH de Cornouailles
-
Reims, France, 51100
- Recruiting
- CHU de Reims
-
Suresnes, France, 92150
- Recruiting
- Hôpital Foch
-
-
-
-
-
Berlin, Germany, 12351
- Recruiting
- Vivantes Klinikum Neukölln;Klinik für Innere Medizin ? Hämatologie, Onkologie und Palliativmedizin
-
Bielefeld, Germany, 33611
- Recruiting
- Evangelisches Klinikum Bethel, Universitätsklinikum OWL der Universität Bielefeld;Campus Bielefeld-Bethel, Innere Medizin, Hämatologie/Onkologie, Stammzelltransplantation und Palliativmedizin
-
Essen, Germany, 45147
- Recruiting
- Universitätsklinikum Essen
-
Esslingen am Neckar, Germany, 73730
- Recruiting
- Klinikum Esslingen
-
-
-
-
-
Athens, Greece, 124 61
- Recruiting
- Attikon University General Hospital
-
Marousi, Greece, 151 25
- Recruiting
- Athens Medical Center
-
Thessaloniki, Greece, 55236
- Recruiting
- Ag. Loukas Hospital
-
Thessaloniki, Greece, 570 01
- Recruiting
- Interbalkan Medical Center of Thessaloniki
-
-
-
-
-
Hong Kong, Hong Kong
- Recruiting
- Queen Mary Hospital
-
Shatin, Hong Kong
- Recruiting
- Prince of Wales Hosp
-
-
-
-
-
Cork, Ireland, T12 DC4A
- Recruiting
- Cork University Hospital
-
Dublin, Ireland, D08 NHY1
- Recruiting
- St James' Hospital
-
-
-
-
Lazio
-
Rome, Lazio, Italy, 00144
- Recruiting
- IRCCS Istituto Regina Elena (IFO)
-
-
Lombardy
-
Bergamo, Lombardy, Italy, 24121
- Recruiting
- Humanitas Gavazzeni
-
Milan, Lombardy, Italy, 20133
- Recruiting
- IRCCS Istituto Nazionale Dei Tumori (INT)
-
-
Tuscany
-
Florence, Tuscany, Italy, 50139
- Recruiting
- Azienda Ospedaliero-Universitaria Careggi
-
-
Umbria
-
Perugia, Umbria, Italy, 06156
- Recruiting
- Azienda Ospedaliera Di Perugia Ospedale s. Maria Della Misericordia
-
-
Veneto
-
Peschiera Del Garda (VR), Veneto, Italy, 37019
- Recruiting
- Ospedale P. Pederzoli Casa di cura Privata
-
-
-
-
-
Gifu, Japan, 501-1194
- Recruiting
- Gifu University Hospital
-
Hiroshima, Japan, 734-8551
- Recruiting
- Hiroshima University Hospital
-
Hyōgo, Japan, 650-0017
- Recruiting
- Kobe University Hospital
-
Ōita, Japan, 879-5593
- Recruiting
- Oita University Hospital
-
-
-
-
-
Bystra, Poland, 43-360
- Recruiting
- Centrum Pulmonologii i Torakochirurgii
-
Gda?sk, Poland, 80-214
- Recruiting
- Uniwersyteckie Centrum Kliniczne, O?rodek Bada? Klinicznych Wczesnych Faz
-
Kielce, Poland, 25-734
- Recruiting
- ?wi?tokrzyskie Centrum Onkologii Samodzielny Publiczny Zak?ad Opieki Zdrowotnej w Kielcach;Klinika Onkologii Klinicznej
-
Olsztyn, Poland, 10-357
- Recruiting
- Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie
-
Warsaw, Poland, 01-138
- Recruiting
- Instytut Gruzlicy i Chorob Pluc;Klinika Nowotworow Klatki Piersiowej
-
Wroc?aw, Poland, 53-439
- Recruiting
- Dolno?L?Skie Centrum Onkologii, Pulmonologii I Hematologii
-
-
-
-
-
Lisbon, Portugal, 1350-352
- Recruiting
- Hospital CUF Tejo
-
Lisbon, Portugal, 1400-038
- Recruiting
- Centro Clinico Champalimaud
-
Loures, Portugal, 2674-514
- Recruiting
- Hospital Beatriz Angelo
-
-
-
-
-
Busan, South Korea, 602-739
- Recruiting
- Pusan National University Hospital
-
Daegu, South Korea, 41404
- Recruiting
- Kyungpook National University Chilgok Hospital
-
Daegu, South Korea, 42415
- Recruiting
- Yeungnam University Medical Center
-
Daejeon, South Korea, 35015
- Recruiting
- Chungnam National University Hospital
-
Gyeonggi-do, South Korea, 16499
- Recruiting
- Ajou University Medical Center
-
Incheon, South Korea, 21565
- Recruiting
- Gachon University Gil Medical Center
-
Jeollanam-do, South Korea, 58128
- Recruiting
- Chonnam National University Hwasun Hospital
-
Seoul, South Korea, 05505
- Recruiting
- Asan Medical Center
-
Seoul, South Korea, 03722
- Recruiting
- Severance Hospital, Yonsei University Health System
-
-
Gyeonggido
-
Seongnam-si, Gyeonggido, South Korea, 13620
- Recruiting
- Seoul National University Bundang Hospital
-
-
-
-
-
A Coruña, Spain, 15006
- Recruiting
- Complejo Hospitalario Universitario A Coruña (CHUAC)
-
Alicante, Spain, 03010
- Recruiting
- Hospital General Univ. de Alicante
-
Granada, Spain, 18016
- Recruiting
- Hospital Universitario San Cecilio
-
Madrid, Spain, 28041
- Recruiting
- Hospital Universitario 12 de Octubre
-
Málaga, Spain, 29010
- Recruiting
- Hospital Clinico Universitario Virgen de la Victoria
-
Seville, Spain, 41013
- Recruiting
- Hospital Universitario Virgen del Rocio
-
Zaragoza, Spain, 50009
- Recruiting
- Hospital Universitario Miguel Servet
-
-
Balearic Islands
-
Palma de Mallorca, Balearic Islands, Spain, 07198
- Recruiting
- Hospital Son Llatzer
-
-
Barcelona
-
Badalona, Barcelona, Spain, 08916
- Recruiting
- ICO Badalona-H.U. Germans Trias i Pujol
-
Sabadell, Barcelona, Barcelona, Spain, 08208
- Recruiting
- Corporacio Sanitaria Parc Tauli
-
-
Tenerife
-
Santa Cruz de Tenerife, Tenerife, Spain, 38010
- Recruiting
- Complejo Hospitalario Nuestra Señora de la Candelaria
-
-
Vizcaya
-
Bilbao, Vizcaya, Spain, 48013
- Recruiting
- Hospital de Basurto
-
-
-
-
-
London, United Kingdom, NW1 2PG
- Recruiting
- University College London Hospital
-
-
-
-
California
-
Clovis, California, United States, 93611
- Recruiting
- Community Cancer Institute (CCI)
-
-
Florida
-
Bay Pines, Florida, United States, 33744
- Recruiting
- Bay Pines VA Healthcare System
-
-
Georgia
-
Atlanta, Georgia, United States, 30318
- Recruiting
- Piedmont Cancer Institute, PC
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Dana-Farber Cancer Institute
-
-
Michigan
-
Farmington Hills, Michigan, United States, 48334
- Recruiting
- Profound Research, LLC
-
-
Nevada
-
Reno, Nevada, United States, 89502
- Recruiting
- Renown Regional Medical Center
-
Reno, Nevada, United States, 89511
- Recruiting
- Cancer Care Specialists
-
-
New Mexico
-
Farmington, New Mexico, United States, 87401
- Recruiting
- San Juan Oncology Associates
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Recruiting
- The James Cancer Hospital and Solove Research Institute
-
-
Tennessee
-
Memphis, Tennessee, United States, 38120
- Recruiting
- Baptist Clinical Research Institute
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- Histological or cytological diagnosis of clinical Stage II-IIIB NSCLC of either non-squamous or squamous histology
- Participants must have had complete resection of NSCLC
- Prior treatment with neoadjuvant immune checkpoint inhibitor (pembrolizumab or nivolumab) in combination with histology-based platinum-based doublet chemotherapy
- Participants must be randomized within 12 weeks of their surgery date
- No evidence of disease recurrence or metastatic disease
- Documentation of the presence of a KRAS G12C mutation
Exclusion Criteria:
- Participants who achieve pCR following neoadjuvant treatment
- Prior treatment with a KRAS inhibitor or any other anti-cancer therapy not otherwise specified in the protocol
- Prior treatment with radiation therapy for NSCLC, with the exception of localized symptom-directed radiation prior to surgical resection
- Resolved Grade 3 or greater immune-related AE or unresolved Grade 2 or greater immune-related AE from neoadjuvant immunotherapy
- Active or history of autoimmune disease or immune deficiency
- Significant cardiovascular disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Divarasib
Participants will receive divarasib, orally (PO), once daily (QD) for up to 52 cycles (1 cycle = 21 days). |
Divarasib will be administered orally as per the schedule specified in the respective arm.
Other Names:
|
|
Active Comparator: Control: Pembrolizumab or Nivolumab or Observation
Participants will receive either pembrolizumab, nivolumab, or undergo observation, depending on the treatment received prior to surgery. No study treatment will be given to participants who will undergo observation. |
Pembrolizumab will be administered as either a 200 mg intravenous (IV) infusion, every 3 weeks (Q3W) or 395 mg subcutaneous (SC) injection Q3W, for up to 13 cycles (1 cycle = 21 days).
Other Names:
Nivolumab will be administered as either a 480 mg IV infusion, every 4 weeks (Q4W) or 1200 mg SC injection Q4W, for up to 13 cycles (1 cycle = 28 days).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Disease-free Survival (DFS), as Determined by the Investigator
Time Frame: From randomization to disease recurrence or death from any cause (Up to approximately 5 years)
|
From randomization to disease recurrence or death from any cause (Up to approximately 5 years)
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Overall Survival (OS)
Time Frame: From date of randomization to death from any cause (up to approximately 8 years)
|
From date of randomization to death from any cause (up to approximately 8 years)
|
|
DFS Rates at 2 and 3 Years, as Assessed by the Investigator
Time Frame: At Year 2 and Year 3
|
At Year 2 and Year 3
|
|
Number of Participants With Adverse Events (AEs)
Time Frame: From randomization to 60 days after the end of study treatment (up to approximately 8 years)
|
From randomization to 60 days after the end of study treatment (up to approximately 8 years)
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Clinical Trials, Hoffmann-La Roche
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Respiratory Tract Diseases
- Lung Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Lung Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Amino Acids, Peptides, and Proteins
- Proteins
- Antibodies, Monoclonal, Humanized
- Antibodies, Monoclonal
- Antibodies
- Immunoglobulins
- Immunoproteins
- Blood Proteins
- Serum Globulins
- Globulins
- Nivolumab
- pembrolizumab
Other Study ID Numbers
Other Study ID Numbers
- BO45885
- 2025-524263-21-00 (Ctis)
- 2025 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.